


## LRRK2-IN-7

<b>Cat. No.:</b>	HY-152107		
<b>CAS No.:</b>	2307277-93-4		
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>26</sub> N <sub>6</sub> O		
<b>Molecular Weight:</b>	414.5		
<b>Target:</b>	LRRK2		
<b>Pathway:</b>	Autophagy		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (241.25 mM; Need ultrasonic)																					
	<table border="1"> <thead> <tr> <th rowspan="2">Solvent</th> <th rowspan="2">Mass</th> <th colspan="3">Concentration</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Preparing Stock Solutions</td> <td>1 mM</td> <td>2.4125 mL</td> <td>12.0627 mL</td> <td>24.1255 mL</td> </tr> <tr> <td>5 mM</td> <td>0.4825 mL</td> <td>2.4125 mL</td> <td>4.8251 mL</td> </tr> <tr> <td>10 mM</td> <td>0.2413 mL</td> <td>1.2063 mL</td> <td>2.4125 mL</td> </tr> </tbody> </table>	Solvent	Mass	Concentration			1 mg	5 mg	10 mg	Preparing Stock Solutions	1 mM	2.4125 mL	12.0627 mL	24.1255 mL	5 mM	0.4825 mL	2.4125 mL	4.8251 mL	10 mM	0.2413 mL	1.2063 mL	2.4125 mL
Solvent	Mass			Concentration																		
		1 mg	5 mg	10 mg																		
Preparing Stock Solutions	1 mM	2.4125 mL	12.0627 mL	24.1255 mL																		
	5 mM	0.4825 mL	2.4125 mL	4.8251 mL																		
	10 mM	0.2413 mL	1.2063 mL	2.4125 mL																		
	Please refer to the solubility information to select the appropriate solvent.																					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.03 mM); Clear solution																					

### BIOLOGICAL ACTIVITY

<b>Description</b>	LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase inhibitor with an IC <sub>50</sub> of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 0.9 nM (LRRK2 Kinase) <sup>[1]</sup>
<b>In Vitro</b>	LRRK2-IN-7 (compound 25) is both a mouse breast cancer resistance protein (BCRP) substrate (mouse/human BCRP) and a potent human BCRP inhibitor (BCRP IC <sub>50</sub> = 0.12 μM) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	In a 7 day rat dose limiting toxicity study, LRRK2-IN-7 (compound 25) is tolerated with no significant histopathology findings up to 100 mg/kg once a day (AUC <sub>tot</sub> = 330 μM·h) <sup>[1]</sup> . In an acute (2 h) rat PK/PD study, LRRK2-IN-7 (compound 25) demonstrates a dose-dependent decrease in LRRK2 pS935 in

---

rat brain striatum with an EC<sub>50</sub> = 0.18 nM<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

[1]. David A Candito, et al. Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1 H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease. J Med Chem. 2022 Dec 22;65(24):16801-16817.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA